MKRN2 Antibody, Biotin conjugated
-
中文名稱：MKRN2兔多克隆抗體, Biotin偶聯
-
貨號：CSB-PA872420LD01HU
-
規格：￥880
-
其他：
產品詳情
-
產品名稱：Rabbit anti-Homo sapiens (Human) MKRN2 Polyclonal antibody
-
Uniprot No.：
-
基因名：MKRN2
-
別名：MKRN2 antibody; RNF62 antibody; HSPC070Probable E3 ubiquitin-protein ligase makorin-2 antibody; EC 2.3.2.27 antibody; RING finger protein 62 antibody; RING-type E3 ubiquitin transferase makorin-2 antibody
-
宿主：Rabbit
-
反應種屬：Human
-
免疫原：Recombinant Human Probable E3 ubiquitin-protein ligase makorin-2 protein (29-170AA)
-
免疫原種屬：Homo sapiens (Human)
-
標記方式：Biotin
-
克隆類型：Polyclonal
-
抗體亞型：IgG
-
純化方式：>95%, Protein G purified
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 -
產品提供形式：Liquid
-
應用范圍：ELISA
-
Protocols：
-
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產品評價
相關產品
靶點詳情
-
功能：E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins.
-
基因功能參考文獻：
- These results delineate a novel role of MKRN2 in negatively regulating NF-kappaB-mediated inflammatory responses, cooperatively with PDLIM2. PMID: 28378844
- Over-expression of MKRN2 in K562 cells increased cell proliferation. Our results indicated possible roles of MKRN2 in normal and malignant hematopoiesis. PMID: 24675897
- MKRN2 and RAF1 are co-expressed in tissues and cell lines PMID: 11597136
-
組織特異性：Widely expressed.
-
數據庫鏈接：
Most popular with customers
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
-
